Problem Many resource-poor countries have started scaling up antiretroviral therapy (ART). While reports from individual clinics point to successful implementation, there is limited information about progress in government institutions at a national level. Approach Malawi started national ART scale-up in 2004 using a structured approach. There is a focus on one generic, fixed-dose combination treatment with stavudine, lamivudine and nevirapine. Treatment is delivered free of charge to eligible patients with HIV and there is a standardized system for recruiting patients, monthly follow-up, registration, monitoring and reporting of cases and outcomes. All treatment sites receive quarterly supervision and evaluation. Local setting In January 2004, there were nine public sector facilities delivering ART to an estimated 4 000 patients. By December 2005, there were 60 public sector facilities providing free ART to 37 840 patients using national standardized systems. Analysis of quarterly cohort treatment outcomes at 12 months showed 80% of patients were alive, 10% dead, 9% lost to follow-up and 1% had stopped treatment. Lessons learned Achievements were the result of clear national ART guidelines, implementing partners working together, an intensive training schedule focused on clinical officers and nurses, a structured system of accrediting facilities for ART delivery, quarterly supervision and monitoring, and no stock-outs of antiretroviral drugs. The main challenges are to increase the numbers of children, pregnant women and patients with tuberculosis being started on ART, and to avert high early mortality and losses to follow-up. The capacity of the health sector to cope with escalating case loads and to scale up prevention alongside treatment will determine the future success of ART delivery in Malawi. Une traduction en français de ce résumé figure à la fin de l'article. Al final del artículo se facilita una traducción al español.
Background
In December 2003, the World Health Organization(WHO) and the joint United Nations Programme on HIV and AIDS (UNAIDS) launched the "3 by 5" initiative, with the goal of having 3 million people on antiretroviral therapy (ART) in developing countries by the end of 2005. By December 2005, an estimated 1.3 million people from low-and middle-income countries had started treatment, with 810 000 of these living in sub-Saharan Africa. 1 Although the 3 by 5 target was not reached, it has been a remarkable effort, particularly in the challenging working arena of sub-Saharan Africa. Reports Malawi's contribution to "3 by 5": achievements and challenges Edwin 
Scale-up methods
Details of ART delivery in Malawi between 2004 and 2005 have been described elsewhere. 8 A standardized structured approach was used for treatment, details of which are shown in Box 1. 
Results
In early 2004, an estimated 4000 patients had started on ART in the public health sector. By the end of 2005, the number of patients cumulatively started on ART was 37 840, which was 47% of the national target. Characteristics and outcomes of patients started on ART are shown in Table 1 . ART was given to 6680 patients with active or previous tuberculosis, who as a result were staged in WHO clinical stage III or stage IV (18% of those placed on ART), and 336 HIV-positive pregnant women through Prevention of Mother to Child Transmission programmes (1% of those placed on ART).
For reporting purposes, cohorts of patients are grouped by quarters of the calendar year, allowing 6-month and 12-month cohort outcome analyses to be performed. For example, all patients registered in a cohort from January to March 2005 could have their outcomes assessed on 30 September 2005, and these data were included in the 6-month outcome analysis (although we do recognize that this method includes patient outcomes 6-9 months after starting ART). This same cohort at a later time could also have their outcomes assessed on 31 March 2006, with these data being included in the 12-month outcome analysis.
During each of the supervisory and monitoring visits in 2005 and 2006, data from all cohorts of patients at the ART facilities were included in 6-month and 12-month outcome analyses: these were combined to give results which are shown in Fig.1 . Outcomes at 6 months and 12 months were similar, indicating that most deaths in a young programme such as Malawi's occur in the early months of ART.
Discussion Achievements
The Malawian example that we describe shows that using a simple, structured approach to ART delivery, government health sectors can deliver treatment to large numbers of patients fairly quickly with good outcomes. A few facilities in and the presence or absence of side effects being used to judge treatment progress.
• Use of a standardized system for registration, monitoring and reporting of cases and outcomes.
• Quarterly supervision and evaluation of all antiretroviral treatment sites.
was not reached, there has been general satisfaction to date with the achievement in ART scale-up, especially given that trained health care personnel, monitoring tools and systems of drug procurement and distribution were not in place at the beginning of 2004.
There have been several factors responsible for the successes in ART delivery in Malawi. The most important are: clear national ART guidelines, with an emphasis on the system of registration, monitoring and recording of results; agreement by all implementing partners to work with the Ministry of Health and use national standardized systems; an intensive training schedule focused on clinical officers and nurses learning the ART guidelines; a structured system of accrediting ART sites before they are permitted to deliver treatment to patients; quarterly supervision and monitoring of all ART delivery sites by the HIV Unit of the Ministry of Health and its partners; and an ART procurement and distribution system that was associated with no stock-outs of antiretroviral drugs. ART facilities vary in their quality and some do not perform as well as they should. However, regular and structured supervision ensures that a basic standard is always maintained and that data are always collected.
Challenges
There have been several challenges in the scaling-up of ART delivery. Children, HIV-positive pregnant women and patients with tuberculosis were, and still are, under-represented in treatment populations. The new revised 2006 WHO Paediatric Guidelines, 9 and Malawi's revised ART Guidelines, 10 which emphasize the importance of ART for children and recommend prioritizing CD4-lymphocyte counts in HIV-infected pregnant women, should increase the number of children and pregnant women accessing ART. Tuberculosis remains a difficult problem as a result of drug-drug interactions between rifampicin and non-nucleoside reverse transcriptase inhibitors 11 and the fact that in Malawi ART is usually distributed from hospital clinics, whereas delivery of anti-tuberculosis treatment is decentralized and is done from health centres. 12 There is a high early death rate in patients starting ART, similar to that reported from other low-income countries. 13 This finding is related to patients presenting with advanced HIV disease, tuberculosis, bacterial infections, malignancy and immune reconstitution syndrome.
14 An aggressive approach to the diagnosis of tuberculosis before initiating ART and concomitant broadspectrum antibiotic prophylaxis targeted at common serious bacterial infections may be two ways to reduce this problem of early deaths. The number of cases lost to follow-up is also of concern, and operational research is needed to identify the true outcomes of these patients to establish a more complete data set for analysis.
Other challenges to ART scale-up include equitable access to ART sites especially for patients in rural areas, the capacity of the health sector to absorb the extra demands of ART delivery without compromising other aspects of general health care, and the scaling-up of prevention efforts alongside treatment. Enseignements tirés Les résultats ont pu être obtenus grâce à des directives nationales claires sur le traitement antirétroviral, à la collaboration entre les partenaires chargés de la mise en oeuvre, à une formation intensive des cliniciens et des infirmières, à un système structuré d'accréditation des centres appelés à délivrer le traitement, à une supervision et une surveillance trimestrielles, ainsi qu'à un approvisionnement continu en antirétroviraux. Les principaux défis consistent à améliorer le nombre -limité au demeurant -d'enfants, de femmes enceintes et de malades souffrant de la tuberculose et entamant un traitement ARV et à réduire la forte mortalité précoce et le nombre de sujets perdus de vue. L'aptitude du secteur de la santé à faire face au nombre sans cesse plus élevé de cas et à étendre les activités de prévention en plus du traitement est aussi une source de préoccupations. C'est la capacité à relever ces défis qui conditionnera le succès du traitement antirétroviral au Malawi.
Resumen La contribución de Malawi a la iniciativa «tres millones para 2005»: logros y retos
Problema Muchos países con escasos recursos han iniciado una expansión del tratamiento antirretrovírico (TAR). Aunque los informes de algunas clínicas señalan el éxito de la iniciativa, hay escasa información sobre los progresos realizados en las instituciones gubernamentales a nivel nacional. Estrategia Malawi comenzó en 2004 la expansión nacional del TAR con una estrategia estructurada, centrada en el tratamiento con un genérico consistente en la combinación de estavudina, lamivudina y nevirapina a dosis fijas. El tratamiento es ofrecido gratuitamente a los pacientes infectados por VIH que cumplen los criterios, y hay un sistema normalizado de reclutamiento de los pacientes, seguimiento mensual, registro, y monitorización y notificación de los casos y los resultados. Todos los lugares donde se dispensa el tratamiento son supervisados y evaluados trimestralmente. Entorno local En enero de 2004 había nueve centros del sector público que proporcionaban TAR a unos 4 000 pacientes. En diciembre de 2005 había 60 centros del sector público que proporcionaban TAR gratuito a 37 840 pacientes en el marco de los sistemas nacionales normalizados. El análisis de los resultados trimestrales del tratamiento de las cohortes a los 12 meses reveló que el 80% de los pacientes estaban vivos y el 10% muertos, mientras que en el 9% se había interrumpido el seguimiento y en el 1% se había detenido el tratamiento. Enseñanzas Los logros se debieron a la existencia de directrices nacionales claras sobre el TAR, al trabajo en colaboración con los asociados, a un plan intensivo de formación centrado en los ayudantes clínicos y las enfermeras, a un sistema estructurado de acreditación de los centros dispensadores de TAR, a la supervisión y monitorización trimestrales, y al hecho de que nunca se agotaran las existencias de antirretrovíricos. Los principales retos consisten en aumentar el número de niños, embarazadas y pacientes tuberculosos que reciben TAR, y evitar la elevada mortalidad inicial y las interrupciones del seguimiento. La capacidad del sector de la salud para hacer frente al aumento del número de casos y la ampliación de la prevención a la par del tratamiento serán determinantes del éxito futuro del TAR en Malawi. 
